Key Highlights

  • Basel Medical Group was quoted 8.81% higher pre-market on November 18, 2026, at USD 0.3531 against a calculated USD 0.3245 prior close, a gain of USD 0.0286.
  • A registered direct Placement announced October 9, 2026 issued 6 million units at USD 1.33, bringing approximately USD 7.98 million gross and USD 7.28 million net.
  • Shares expected after the deal number around 7,582,111, compared with 1,582,111 beforehand, a calculated 379.2% expansion that excludes 6 million common warrants.
  • The common warrants carry a five-year term and a zero-cash exercise feature that could create as many as 6 million extra shares.

Calculated Prior Close and Share Count Behind the Pre-Market Gain for Basel Medical Group (NASDAQ:BMGL)

Before the regular session, Basel Medical Group is indicated at USD 0.3531, implying a rise of 8.81%. Working back from that level produces a calculated November 17, 2026 close of USD 0.3245, leaving a USD 0.0286 difference. If roughly 7,582,111 shares are in issue following the October financing, the calculated Market Value would sit near USD 2.68 million, though the present share total was not confirmed.

No Same-Day Catalyst, but an October Placement Still Shapes the Story for Basel Medical Group

Coverage did not connect any event to the November 18, 2026 move for Basel Medical Group, so only general background is offered. Thin trading can exaggerate such moves. Micro-caps trading below a dollar frequently react to thin float once a financing has settled. October's registered direct placement, announced October 9, 2026, is the latest corporate development for Basel Medical Group. The Singapore-based provider runs clinics chiefly for corporate customers across construction, marine and oil and gas. Every unit in the 6 million unit placement sold at USD 1.33 and combined one ordinary share or pre-funded Warrant with a common warrant usable at 110% of that price over five years. A December 1, 2025 Nasdaq delinquency notice tied to a fiscal 2025 Annual Report lacking an auditor opinion was disclosed, with trading unaffected.

Dilution Math, Thin Liquidity and Nano-Cap Exposure at Basel Medical Group

Share issuance dominates the risk discussion. Moving from 1,582,111 shares to about 7,582,111 equals a calculated 379.2% increase, and 6 million common warrants alongside a zero-cash exercise option could add up to another 6 million shares. A calculated market value near USD 2.68 million sits far below USD 100 million, which places the company in nano-cap territory where moves of 8% can appear without news. The indicated price is a calculated 73.5% beneath the USD 1.33 placement level. Published coverage cites fiscal 2025 Revenue of SGD 11.3 million, a 12.6% increase, but recent cash, profit and Debt figures could not be found for Basel Medical Group.

Where Things Stand

Basel Medical Group is indicated 8.81% higher at USD 0.3531 before the November 18, 2026 session, a calculated USD 0.0286 advance from USD 0.3245. Nothing specific was identified as the trigger. The most recent corporate step is the October 9, 2026 placement of 6 million units at USD 1.33, which enlarged the share base and attached 6 million common warrants. Dilution, warrant overhang and a calculated market value near USD 2.68 million are the principal worries, and early quotes can reverse once regular trading starts. Nothing here is Investment advice.